The Milner Therapeutics Institute is a global therapeutic alliance based in Cambridge, which aims to transform pioneering science into therapies. It is a new paradigm for an academic Institution, based on bridging the gap between academia and Industry. The institute is the hub of 80 Affiliated Organisations world-wide and will have its own Research Labs within the Capella building at the Biomedical Campus, due to open in 2019.
The Institute was co-founded by Tony Kouzarides and Jonathan Milner. The therapeutics concept and mission was developed following the establishment of the Therapeutics Consortium by Tony Kouzarides. Jonathan Milner is a benefactor to the building of the Research Laboratories, which bear his name. Tony and Jonathan are also co-founders of Abcam plc, an antibody reagents provider based in Cambridge.
The Milner Therapeutics Institute is led by its Director Tony Kouzarides and Deputy Director Kathryn Chapman. The institute will move from the Gurdon Institute and open mid-2019 in the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for collaboration between industry and academia. Tony Kouzarides will retain his current laboratory at the Gurdon Institute once the team moves to its new premises.